Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 1, 2022, regarding events occurring on February 28, 2022. The filing details executive compensation decisions made by the Compensation Committee and the resignation of a Board director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and governance changes.
Material Changes and Executive Compensation
The Compensation Committee awarded 2021 annual bonuses and approved 2022 base salaries and bonus targets for named executive officers. Additionally, equity awards were granted.
- 2021 Annual Bonuses Awarded:
- Mihael Polymeropoulos (CEO): $596,744
- Kevin Moran (CFO): $175,473
- Timothy Williams (General Counsel): $192,060
- Aranthan "AJ" Jones II (Resigned Oct 2021): $136,843
- Joakim Wijkstrom (CMO): $227,853
- 2022 Base Salaries and Bonus Targets:
- Mihael Polymeropoulos: $815,140 salary; 80% target bonus
- Kevin Moran: $426,120 salary; 45% target bonus
- Timothy Williams: $466,400 salary; 45% target bonus
- Joakim Wijkstrom: $553,320 salary; 45% target bonus
- Equity Grants (Feb 28, 2022):
- Stock Options: Exercise price of $11.36 per share. Vesting begins 25% on Feb 28, 2023, with the remainder over 36 months.
- Restricted Stock Units (RSUs): Vest in four equal annual installments starting March 1, 2023.
- Grant Sizes: CEO received 275,000 options and 115,000 RSUs; CFO, General Counsel, and CMO each received 77,500 options and 32,700 RSUs.
Board Governance Changes
H. Thomas Watkins notified the Board of his resignation as a Class I director, effective at the 2022 Annual Meeting of Stockholders. The Board will reduce the number of directors from six to five. A current director will be appointed to succeed Mr. Watkins as Lead Independent Director and Chairman of the Compensation and Nominating/Corporate Governance Committees.
Outlook and Risks
The filing contains no forward-looking guidance, risk factors, or discussion of contingencies beyond the standard vesting schedules for equity awards.
Key Facts for Investor Verification
- Verify the total cash compensation cost for 2021 bonuses and 2022 salary increases against the company's cash position.
- Confirm the dilution impact of the 585,000 new stock options and 213,100 RSUs granted to executives.
- Monitor the appointment of the new Lead Independent Director and Committee Chairmen following Mr. Watkins' resignation.
- Note that Aranthan "AJ" Jones II received a 2021 bonus despite resigning in October 2021.